Mr. Kang Tae-suk will be also responsible of the advancement of BGM-27 and Tau NonTangles™ into the market after Phase I of the project.
(1888PressRelease) December 09, 2019 - Biogenum (ISIN: KR7013369996), a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration, is pleased to announce the appointment of Kang Tae-suk, Pharma Medical Doctor as Senior Vice President, Head of Regulatory Affairs. Dr. Tae-suk brings over 20 years of global regulatory affairs experience with investigational and commercialized products across a range of Central Nervous System disorders, including schizophrenia, bipolar disorder, depression, Alzheimer’s disease, and Parkinson’s disease.
Dr. Tae-suk has held positions of increasing responsibility and scope in Regulatory Affairs at a top medical laboratory over the last 14 years. He has overseen a wide array of submissions and approvals for the company’s top products.
Dr. Tae-suk received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degree from the Medical University of Hong Kong. He also did a Post-Doctoral Fellowship jointly sponsored by the University.
“We are delighted to welcome him to our team. Dr. Kang has strong global regulatory strategy experience for indications relevant to our pipeline and has been involved in over 10 new and 30 supplemental drug approvals. We believe his expertise further strengthens our leadership in the development of treatments for Central Nervous System diseases,” said Dr. Yoon Hae-joo, Executive Vice President and Chief Medical Officer of Biogenum.
“I am enthusiastic about joining the team at Biogenum and look forward to contributing to the advancement of the BGM-18 immunotherapy targeting Abeta programs in Alzheimer and other neuropsychiatric disorders including bipolar disorder, agitation associated with dementia, and depressive disorders, as well as the advancement of BGM-27 and Tau NonTangles™,” stated Dr. Tae-suk.
About Biogenum
Biogenum is a privately held biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer's disease, Parkinson's disease, ALS and others. The quality, simplicity and sensitivity of its products brings precision medicine within reach. Composed of proprietary chemistry and software, Biogenum delivers powerful answers using broadly installed instrument platforms. The company’s leadership team has decades of experience in drug discovery, translational strategy, corporate development and commercialization. Collectively, we have been instrumental in researching more than 10 drugs to be delivered in the market.
Mr. Kang Tae-suk will be also responsible of the advancement of BGM-27 and Tau NonTangles™ into the market after Phase I of the project. 
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam